About Microbiome Sequencing Services
Microbiome sequencing helps in analyzing microbial communities found in the human body and finding their impact on disease diagnosis.
Technavio’s analysts forecast the global microbiome sequencing services market to grow at a CAGR of 22.10% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global microbiome sequencing services market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Microbiome Sequencing Services Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• BGI
• Clinical-Microbiomics
• Diversigen
• GATC Biotech
• Second Genome
Market driver
• Rise in chronic and infectious diseases
• For a full, detailed list, view our report
Market challenge
• High cost of sequencing systems
• For a full, detailed list, view our report
Market trend
• Growing awareness of microbiome in cancer development and therapy
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: CUSTOMER LANDSCAPE
PART 08: MARKET SEGMENTATION BY END-USER
• Overview
• Comparison by end-user
• Pharmaceutical and biotechnology companies
• Academic institutes and research laboratories
• Others
• Market opportunity by end-user
PART 09: REGIONAL LANDSCAPE
• Overview
• Regional comparison
• Americas
• EMEA
• APAC
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Growing awareness of microbiome in cancer development and therapy
• Growing demand for highly accurate forensic tools
• Increasing adoption of microbiome sequencing in clinical workflows
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• BGI
• Clinical-Microbiomics
• Diversigen
• GATC Biotech
• Second Genome
• Other prominent vendors
PART 15: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Related market
Exhibit 02: Market characteristics
Exhibit 03: Market segments
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2017
Exhibit 06: Validation techniques employed for market sizing 2017
Exhibit 07: Global microbiome sequencing services market – Market size and forecast 2017-2022 ($ mn)
Exhibit 08: Global microbiome sequencing services market – Year over year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Market condition: Five forces 2022
Exhibit 18: Customer landscape
Exhibit 19: End-user – Market share 2017-2022 (%)
Exhibit 20: Comparison by end-user
Exhibit 21: Pharmaceutical and biotechnology companies – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Pharmaceutical and biotechnology companies – Year over year growth 2018-2022 (%)
Exhibit 23: Academic institutes and research laboratories – Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Academic institutes and research laboratories – Year over year growth 2018-2022 (%)
Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Others – Year over year growth 2018-2022 (%)
Exhibit 27: Market opportunity by end-user
Exhibit 28: Global – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year over year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year over year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year over year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: R&D funding in $ millions for malaria from 2013-2016
Exhibit 41: R&D funding in $ millions for HIV from 2013-2016
Exhibit 42: Cost of sequencing per genome in $ (2001-2015)
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: BGI: Overview
Exhibit 49: BGI: Business segments
Exhibit 50: BGI: Organizational developments
Exhibit 51: BGI: Geographic focus
Exhibit 52: BGI: Segment focus
Exhibit 53: BGI: Key offerings
Exhibit 54: Clinical-Microbiomics: Overview
Exhibit 55: Clinical-Microbiomics: Business segments
Exhibit 56: Clinical-Microbiomics: Organizational developments
Exhibit 58: Clinical-Microbiomics: Geographic focus
Exhibit 59: Clinical-Microbiomics: Segment focus
Exhibit 60: Clinical-Microbiomics: Key offerings
Exhibit 61: Diversigen: Overview
Exhibit 62: Diversigen – Business segments
Exhibit 63: Diversigen – Organizational developments
Exhibit 64: Diversigen – Geographic focus
Exhibit 65: Diversigen – Segment focus
Exhibit 66: Diversigen – Key offerings
Exhibit 67: GATC Biotech: Overview
Exhibit 68: GATC Biotech: Business segments
Exhibit 69: GATC Biotech: Organizational developments
Exhibit 70: GATC Biotech: Geographic focus
Exhibit 71: GATC Biotech: Segment focus
Exhibit 72: GATC Biotech – Key offerings
Exhibit 73: Second Genome: Overview
Exhibit 74: Second Genome – Business segments
Exhibit 75: Second Genome – Organizational developments
Exhibit 76: Second Genome – Geographic focus
Exhibit 77: Second Genome – Segment focus
Exhibit 78: Second Genome – Key offering
